Wegovy patient instructions: what the PDF leaflet covers and where clinical guidance begins

The myth: the PDF is just paperwork you can skip

Most people filing the patient leaflet straight in a drawer are doing so because they assume it repeats what they already found online. That's understandable, but it's a mistake. The PIL is the legal, MHRA-reviewed document specific to the exact pen format in your hands. It contains injection steps tested and approved for that device, the storage window that applies to that formulation, and the contraindications your prescriber will already have screened you against. Online summaries, including this one, are educational aids. The PIL is the primary source.

The Wegovy 7.2mg single-dose pen, approved by the MHRA on 14 April 2026, has its own dedicated PIL covering its auto-dosing mechanism and covered-needle design. If you have switched from the 2.4mg pens, the instruction steps are not identical. Reading the new leaflet matters.

The NHS semaglutide medicines page offers a reliable plain-English summary of how Wegovy works and its main side effects, and is a good complement to the PIL if some of the clinical language needs unpacking. That said, it will always direct you back to your own healthcare team and your specific leaflet for anything dose-specific.

What the Wegovy PIL actually walks you through

The leaflet is structured around five practical sections: what Wegovy is and what it is used for; what you need to know before you use it; how to use it; possible side effects; and storage. The injection-technique section is the part most people read first, and rightly so. It covers selecting and rotating sites (abdomen, thigh, upper arm), preparing the pen, the injection sequence and safe sharps disposal. For a step-by-step visual alternative, video injection guides can help if written instructions feel abstract.

Storage is stated in the PIL in precise terms. The room-temperature window, the refrigeration requirement and what to do if the pen has been left out vary between the 2.4mg and 7.2mg formats. This page won't repeat those figures because the leaflet for your specific pen is the right reference, and any error in a summary could cause a pen to be used outside its safe window.

The contraindications section lists conditions where semaglutide should not be used at all: a personal or family history of medullary thyroid carcinoma or MEN2 syndrome is among them. Your prescriber will have assessed these before issuing a prescription, but knowing they are listed helps you understand why certain questions appear in a clinical consultation. Full administration guidance, including device-specific steps, sits alongside the PIL as a practical reference.

Where the leaflet stops and clinical judgement takes over

The PIL gives instructions for a competent adult following a stable plan. It cannot account for what's happening in your body week to week. Nausea that hasn't settled after two weeks at a given dose, a missed pen mid-titration, a new prescription from another clinician, a planned surgical procedure — these situations need a prescriber's input, not a closer read of the leaflet.

A question our prescribers hear most often is whether it's safe to delay a dose for a specific event. The leaflet sets a general rule; your prescriber can apply clinical judgement to your situation. The same applies to side effects. The PIL lists what to report and what counts as urgent. The MHRA's Yellow Card scheme exists for side effects you want to report formally, and using it contributes to post-market safety monitoring for all patients on semaglutide.

Pancreatitis is worth a specific mention. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines, noting that severe stomach pain spreading to the back, with or without vomiting, requires urgent medical attention. That signal is in the PIL, but it bears repeating plainly here. If that symptom pattern occurs, stop the injection and seek same-day medical help rather than waiting for your next scheduled review.

For context on what treatment typically costs under private supervision, the Wegovy price comparison page sets out what private prescriptions include and what the market looks like since Eli Lilly's 2025 list-price changes affected the wider GLP-1 market.

Getting your instructions into one organised place before you start

A practical approach before your first injection: read the PIL from your box, bookmark the written instructions page for quick reference, and keep the patient support line number your prescriber gave you saved in your phone. If you're reading this the evening before your first pen, that's about as much preparation as you need. The injection itself typically takes under a minute once the technique is familiar.

One thing worth doing the morning you start: put the pen in the fridge door when you unpack it, and set a weekly reminder for the same day and rough time each week. Consistency with timing makes missed doses less likely and keeps the titration schedule on track. If you are considering starting Wegovy and haven't yet had a clinical assessment, our team at nume reviews consultations the same day a real clinician reads your answers, not automated triage. More background on semaglutide and how it works as a treatment is available if you want to read further before deciding.

When you're ready to take the clinical step, speak to our prescribers through a free consultation and get a personalised assessment from a GPhC-registered Independent Prescriber.